Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging high-throughput drug target validation technologies.

Leodevico L Ilag1, Jocelyn H Ng, Gerald Beste

  • 1Xerion Pharmaceuticals, Fraunhoferstr. 9, 82152 Martinsried, Germany. l.ilag@xerion-pharma.com

Drug Discovery Today
|January 28, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Are Long-Chain Polyunsaturated Fatty Acids the Link between the Immune System and the Microbiome towards Modulating Cancer?

Medicines (Basel, Switzerland)·2018
Same author

Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study.

Leukemia & lymphoma·2018
Same author

A pilot single centre, double blind, placebo controlled, randomized, parallel study of Calmagen® dermaceutical cream and lotion for the topical treatment of tinea and onychomycosis.

BMC complementary and alternative medicine·2017
Same author

Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma.

Molecular therapy oncolytics·2016
Same author

Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.

Journal of hepatology·2016
Same author

Generation of a Novel Bacteriophage Library Displaying scFv Antibody Fragments from the Natural Buffalo Host to Identify Antigens from Adult Schistosoma japonicum for Diagnostic Development.

PLoS neglected tropical diseases·2015
Same journal

Validation of AI-enabled surrogate models in quantitative systems pharmacology: a practical, context-of-use-driven review.

Drug discovery today·2026
Same journal

IdopNetworks: How to infer the individualized genetic architecture of genomics for precision medicine.

Drug discovery today·2026
Same journal

Organoid-AI platforms need integrated governance in drug discovery.

Drug discovery today·2026
Same journal

Inorganic nanoparticles for diagnostics, drug delivery and therapy for solid tumors.

Drug discovery today·2026
Same journal

HDAC11 as a potential therapeutic target for Alzheimer's disease.

Drug discovery today·2026
Same journal

From biologics to small-molecule modulators: the evolving landscape of interleukin-targeted therapeutics.

Drug discovery today·2026
See all related articles

Finding the right drug targets is key for pharmaceutical development. Confirming a gene

Area of Science:

  • Genomics and Drug Discovery
  • Molecular Biology and Disease Causation

Background:

  • Drug development faces a bottleneck in identifying valid targets.
  • The genomics revolution has created an abundance of potential drug targets.
  • Correlative data alone is insufficient for target validation.

Purpose of the Study:

  • To emphasize the critical need for target validation in drug discovery.
  • To highlight the shift from target scarcity to target surplus.
  • To underscore the importance of confirming causative roles in disease.

Main Methods:

  • Review of challenges in pharmaceutical and biotech target identification.
  • Analysis of the impact of genomics on drug discovery pipelines.
  • Discussion on the necessity of robust target validation technologies.

Related Experiment Videos

Main Results:

  • A surplus of potential drug targets exists due to genomic advancements.
  • Distinguishing between correlative and causative gene-disease associations is crucial.
  • Effective therapeutic strategies depend on validated targets.

Conclusions:

  • Target validation is essential for successful drug development.
  • Appropriate technologies are required to confirm the causative role of gene products in disease.
  • Overcoming the target validation bottleneck is critical for the pharmaceutical industry.